New hormones in the therapeutic arsenal of chronic renal failure. Growth hormone and erythropoietin.
Although the benefits of rhGH and r-HuEPO therapy in children with CRF and on dialysis are already significant, further study of these new additions to the therapeutic arsenal remains necessary. Data on the final adult height achieved in patients who receive rhGH are extremely important information that is as yet unavailable. The risks and benefits of raising the target hematocrit to a "normal" value in patients receiving r-HuEPO remains under study. Only when these and other issues are soundly evaluated will the full impact of these medications be understood.
Warady
B A
BA
Department of Pediatrics, University of Missouri, Kansas City School of Medicine, USA.
Jabs
K
K
D000818:Animals; D002648:Child; D004921:Erythropoietin / Q000627:therapeutic use*; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy*
D004921:Erythropoietin; D013006:Growth Hormone